What sermorelin is

• What sermorelin is and why the 29-residue fragment keeps full GHRH activity
• How the GHRH receptor, the GH pulse, and the IGF-1 axis actually work
• Why preserving pulsatility is the pharmacologic argument over recombinant GH
• How to read the pediatric, adult, and community evidence tier by tier
• Where sermorelin stands as a compounded product and under anti-doping rules

1. 01 What sermorelin is The hypothalamic fragment that tells the pituitary to make growth hormone free
2. 02 Chemistry and structure A defined 29-residue fragment that carries the whole GHRH signal paid
3. 03 The GHRH receptor One receptor, a cAMP cascade, and the biology of a single GH pulse paid
4. 04 The GH and IGF-1 axis From a pituitary pulse to IGF-1, and back again through feedback paid
5. 05 Pediatric growth hormone deficiency The approved past: sermorelin’s strongest, and oldest, direct evidence paid
6. 06 Adult use and the evidence The off-label present: real mechanism, small studies, and honest limits paid
7. 07 Compared with other GH secretagogues Sermorelin in a crowded field: analogs, secretagogues, and rhGH paid
8. 08 Dosing and administration How sermorelin is prepared and given, for education only paid
9. 09 Safety and product quality What is reported, what is theoretical, and what is unknown paid
10. 10 Administration and the regulatory landscape A compounded peptide in a shifting regulatory world paid
11. 11 Final exam and certification Pass the final exam to earn your specialist certificate. exam

Before any detail, hold the whole idea in one sentence. Sermorelin does not add growth hormone to the body. It hands the pituitary the same start signal the hypothalamus uses, and the pituitary releases a pulse of its own GH.

Because the pituitary and its feedback loops stay in charge, the response is self-limiting. That single feature, working with the body rather than overriding it, is the thread running through everything else in this course.

The story starts with a tumor. In 1982 Guillemin and colleagues isolated GHRH from a pancreatic tumor that was causing acromegaly, finally naming the long-sought hypothalamic factor that switches on growth hormone.

The key nuance is why the drug left the market. Geref was withdrawn for commercial reasons, and the FDA formally said so, which is exactly what later made the ingredient eligible for compounding rather than banned.

The central pharmacologic argument for sermorelin is a shape, not a size. Natural GH arrives in pulses, with the biggest one just after you fall asleep. Recombinant GH instead holds the level high and flat.

Pulsatility is not a cosmetic detail. The gaps between pulses let receptors reset and keep feedback intact, which is why preserving the pulse is treated as a feature rather than a limitation.

Sermorelin invites hype, so set the ceiling before the science. The evidence is genuinely uneven: strong where it is old and clinical, and thin exactly where the marketing is loudest.

Keeping these tiers apart is the entire discipline of the course. The pediatric data are genuinely solid, the short-term hormone changes are believable, and the sweeping adult promises rest on extrapolation rather than trials. Confusing one tier for another is exactly how honest education slides into marketing.

A few claims you will meet online, held against the tiers above. Most are not simply false. They are real but modest findings that get rounded up into transformations as they travel from journals to sales pages.

The skill this course builds is reading each claim against its tier. When a source states an exact adult benefit with confidence, that confidence itself is usually the red flag.